The company

Borea Therapeutics is an innovative biotech start-up located in Milan, and co-founded by Professor Paul Heppenstall and  EMBLEM, the technology transfer partner of EMBL (European Molecular Biology Laboratory), and backed by Sofinnova Partners.

Our technology, based upon chemical modification of adeno-associated viral vectors (AAV) builds on scientific discoveries generated at EMBL.